Imaging Features of Pulmonary Immune-related Adverse Events.

CTLA-4 antigen Drug-related side effects and adverse reactions Immunotherapy Pneumonitis Programmed cell death 1 receptor

Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235

Informations de publication

Date de publication:
09 2021
Historique:
received: 31 07 2020
revised: 05 03 2021
accepted: 16 05 2021
pubmed: 5 6 2021
medline: 15 9 2021
entrez: 4 6 2021
Statut: ppublish

Résumé

Pulmonary immune-related adverse events represent rare but potentially severe side effects of immunotherapies. Diagnosis is often challenging, as symptoms and imaging features are not specific and may mimic other lung diseases, thus potentially delaying appropriate patient management. In this setting, an accurate imaging evaluation is essential for a prompt detection and correct management of these drug-induced lung diseases. The purpose of this article is to review the different types of pulmonary immune-related adverse events, describe their imaging characteristics on both high-resolution computed tomography and positron emission tomography/computed tomography and stress their underlying diagnostic challenge by presenting the mimickers.

Identifiants

pubmed: 34087477
pii: S1556-0864(21)02188-2
doi: 10.1016/j.jtho.2021.05.017
pii:
doi:

Substances chimiques

CTLA-4 Antigen 0
Programmed Cell Death 1 Receptor 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1449-1460

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Auteurs

Chiara Pozzessere (C)

Department of Radiology, AUSL Toscana Centro, San Giuseppe Hospital, Empoli, Italy; Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. Electronic address: chiara.pozzessere@gmail.com.

Romain Lazor (R)

Respiratory Medicine Department, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Raphael Jumeau (R)

Department of Radiation Oncology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Solange Peters (S)

Medical Oncology Department, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

John O Prior (JO)

Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Catherine Beigelman-Aubry (C)

Department of Radiodiagnostic and Interventional Radiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH